27842161|t|Netarsudil Increases Outflow Facility in Human Eyes Through Multiple Mechanisms
27842161|a|Netarsudil is a Rho kinase/norepinephrine transporter inhibitor currently in phase 3 clinical development for glaucoma treatment. We investigated the effects of its active metabolite, netarsudil-M1, on outflow facility (C), outflow hydrodynamics, and morphology of the conventional outflow pathway in enucleated human eyes. Paired human eyes (n = 5) were perfused with either 0.3 Î¼M netarsudil-M1 or vehicle solution at constant pressure (15 mm Hg). After 3 hours, fluorescent microspheres were added to perfusion media to trace the outflow patterns before perfusion - fixation. The percentage effective filtration length (PEFL) was calculated from the measured lengths of tracer distribution in the trabecular meshwork (TM), episcleral veins (ESVs), and along the inner wall (IW) of Schlemm's canal after global and confocal imaging. Morphologic changes along the trabecular outflow pathway were investigated by confocal, light, and electron microscopy. Perfusion with netarsudil-M1 significantly increased C when compared to baseline (51%, P < 0.01) and to paired controls (102%, P < 0.01), as well as significantly increased PEFL in both IW (P < 0.05) and ESVs (P < 0.01). In treated eyes, PEFL was significantly higher in ESVs than in the IW (P < 0.01) and was associated with increased cross-sectional area of ESVs (P < 0.01). Percentage effective filtration length in ESVs positively correlated with the percentage change in C (R2 = 0.58, P = 0.01). A significant increase in juxtacanalicular connective tissue (JCT) thickness (P < 0.05) was found in treated eyes compared to controls. Netarsudil acutely increased C by expansion of the JCT and dilating the ESVs, which led to redistribution of aqueous outflow through a larger area of the IW and ESVs.
27842161	0	10	Netarsudil	T121	C1254351
27842161	11	20	Increases	T169	C0442805
27842161	21	37	Outflow Facility	T060	C0430894
27842161	41	46	Human	T016	C0086418
27842161	47	51	Eyes	T023	C0015392
27842161	60	68	Multiple	T081	C0439064
27842161	69	79	Mechanisms	T169	C0441712
27842161	80	90	Netarsudil	T121	C1254351
27842161	96	143	Rho kinase/norepinephrine transporter inhibitor	T121	C0033671
27842161	157	185	phase 3 clinical development	T062	C0282461
27842161	190	198	glaucoma	T047	C0017601
27842161	199	208	treatment	T061	C0087111
27842161	252	262	metabolite	T123	C0870883
27842161	264	277	netarsudil-M1	T121	C1254351
27842161	282	298	outflow facility	T060	C0430894
27842161	300	301	C	T060	C0430894
27842161	304	311	outflow	T039	C1254359
27842161	312	325	hydrodynamics	T070	C2936194
27842161	331	341	morphology	T080	C0332437
27842161	349	361	conventional	T080	C0439858
27842161	362	377	outflow pathway	T077	C1705987
27842161	381	402	enucleated human eyes	T037	C1396718
27842161	404	410	Paired	T080	C1709450
27842161	411	416	human	T016	C0086418
27842161	417	421	eyes	T023	C0015392
27842161	435	443	perfused	T061	C0031001
27842161	463	476	netarsudil-M1	T121	C1254351
27842161	480	496	vehicle solution	T122	C0042444
27842161	500	517	constant pressure	T067	C0033095
27842161	538	543	hours	T079	C0439227
27842161	545	569	fluorescent microspheres	T074	C0026032
27842161	584	593	perfusion	T061	C0031001
27842161	594	599	media	T130	C0009924
27842161	603	608	trace	T081	C1552622
27842161	613	629	outflow patterns	T039	C1254359
27842161	637	646	perfusion	T061	C0031001
27842161	649	657	fixation	T061	C0185023
27842161	663	701	percentage effective filtration length	T081	C1444754
27842161	703	707	PEFL	T081	C1444754
27842161	733	741	measured	T080	C0444706
27842161	742	749	lengths	T081	C1444754
27842161	753	759	tracer	T130	C1522485
27842161	760	772	distribution	T169	C1704711
27842161	780	799	trabecular meshwork	T023	C0040573
27842161	801	803	TM	T023	C0040573
27842161	806	822	episcleral veins	T023	C0226616
27842161	824	828	ESVs	T023	C0226616
27842161	845	855	inner wall	T082	C1254362
27842161	857	859	IW	T082	C1254362
27842161	864	879	Schlemm's canal	T030	C0229108
27842161	886	892	global	T080	C2348867
27842161	897	913	confocal imaging	T059	C0242842
27842161	915	934	Morphologic changes	T190	C1260954
27842161	945	955	trabecular	T023	C0040573
27842161	956	971	outflow pathway	T077	C1705987
27842161	993	1001	confocal	T059	C0242842
27842161	1003	1008	light	T059	C0430389
27842161	1014	1033	electron microscopy	T059	C0026019
27842161	1035	1044	Perfusion	T061	C0031001
27842161	1050	1063	netarsudil-M1	T121	C1254351
27842161	1064	1077	significantly	T078	C0750502
27842161	1078	1087	increased	T081	C0205217
27842161	1088	1089	C	T060	C0430894
27842161	1139	1145	paired	T080	C1709450
27842161	1184	1197	significantly	T078	C0750502
27842161	1198	1207	increased	T081	C0205217
27842161	1208	1212	PEFL	T081	C1444754
27842161	1221	1223	IW	T082	C1254362
27842161	1239	1243	ESVs	T023	C0226616
27842161	1267	1271	eyes	T023	C0015392
27842161	1273	1277	PEFL	T081	C1444754
27842161	1282	1295	significantly	T078	C0750502
27842161	1306	1310	ESVs	T023	C0226616
27842161	1323	1325	IW	T082	C1254362
27842161	1345	1360	associated with	T080	C0332281
27842161	1361	1370	increased	T081	C0205217
27842161	1371	1391	cross-sectional area	T082	C0205146
27842161	1395	1399	ESVs	T023	C0226616
27842161	1412	1450	Percentage effective filtration length	T081	C1444754
27842161	1454	1458	ESVs	T023	C0226616
27842161	1511	1512	C	T060	C0430894
27842161	1538	1549	significant	T078	C0750502
27842161	1550	1558	increase	T169	C0442805
27842161	1562	1596	juxtacanalicular connective tissue	T024	C0009780
27842161	1598	1601	JCT	T024	C0009780
27842161	1603	1612	thickness	T080	C1280412
27842161	1645	1649	eyes	T023	C0015392
27842161	1672	1682	Netarsudil	T121	C1254351
27842161	1683	1690	acutely	T079	C0205178
27842161	1691	1700	increased	T081	C0205217
27842161	1701	1702	C	T060	C0430894
27842161	1723	1726	JCT	T024	C0009780
27842161	1744	1748	ESVs	T023	C0226616
27842161	1763	1777	redistribution	T169	C0332620
27842161	1789	1796	outflow	T039	C1254359
27842161	1807	1818	larger area	T082	C0205146
27842161	1826	1828	IW	T082	C1254362
27842161	1833	1837	ESVs	T023	C0226616